[1]
Thaçi, D., Armstrong, A., Gordon, K.B., Blauvelt, A., Paul, C., Boehncke, W.-H., Wang, M., Szilagyi, B. , Hoepken, B., Lambert, J. and Lebwohl, M. 2024. Bimekizumab 3-year Maintenance of Response in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s306. DOI:https://doi.org/10.25251/skin.8.supp.306.